Covid-19 Vaccine: Germany to recognise Bharat Biotech's COVAXIN from June 1
German Ambassador to India Walter J Lindner on Thursday commended the German government for accrediting the WHO-listed Covid-19 vaccine COVAXIN, which was developed by Bharat Biotech, to be used in Germany from June 1.
New Delhi: German Ambassador to India Walter J Lindner on Thursday commended the German government for accrediting the WHO-listed Covid-19 vaccine COVAXIN, which was developed by Bharat Biotech, to be used in Germany from June 1.
WHO released EUL last year
The World Health Organization (WHO) issued an Emergency Use List (EUL) for COVAXIN in November last year, adding to a growing portfolio of validated vaccines for the prevention of Covid-19 caused by SARS-CoV-2 .
Also Read :- India logs 2,323 new Covid cases, 25 deaths
Ambassador praised Germany on Twitter
"I am very pleased that the Government of Germany has decided to recognize COVAXIN as listed by WHO for travel to Germany from 1st June! This embassy is very actively pushing for such a decision (as backlog visa sections have longer waiting times than usual due to covid, please be patient)," Lindner wrote on Twitter.
What is EUL process?
WHO's EUL process assesses the quality, safety and efficacy of COVID-19 vaccines and is a prerequisite for the supply of COVAXIN. It also allows countries to accelerate their own regulatory approvals for the import and administration of Covid-19 vaccines.
'We have the most effective medical equipment'
Dr Mariangela Simao, WHO's assistant director-general for access to medicines and health products, said this emergency use list expands the availability of vaccines. We have the most effective medical equipment to end the Covid-19 pandemic.
DCGI granted EUA to COVAXIN in April
The Drug Controller General of India (DCGI) in April also granted an Emergency Use Authorization (EUA) to COVAXIN for the age group of 6-12 years. Hyderabad-based pharma company Bharat Biotech said in a statement that it has conducted Phase II/III, open-label and multicentre studies to evaluate the safety, reactivity and immunogenicity of Covaccine in healthy children and adolescents aged 2-18 years were.
What is COVAXIN?
Clinical trials conducted in the pediatric population between June 2021 and September 2021 have shown strong safety, responsiveness and immunogenicity. Covaccine is specially designed to provide the same dose for adults and children. COVAXIN is a ready-to-use liquid vaccine, stored at 2-8 °C, with a shelf life of 12 months and a multi-dose vial policy.
Read More :- Latest World News
Click Here - Download The News 24 App